Department of Endocrinology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.
Key Laboratory of Endocrinology Inherited and Metabolic Diseases of Luoyang, Luoyang 471003, China.
Biomed Res Int. 2018 May 13;2018:8639523. doi: 10.1155/2018/8639523. eCollection 2018.
This study is designed to investigate the effect of artemether on type 2 diabetic db/db mice. The experiments consisted of three groups: normal control (NC, db/+, 1% methylcellulose, intragastric administration), diabetic control (DM, db/db, 1% methylcellulose, intragastric administration), and artemether treated (artemether, db/db, 200 mg/kg of artemether, intragastric administration). The treatment lasted for two weeks. The food intake, body weight, and fasting blood glucose of mice were measured every three days. At the start and end of the experiment, the intraperitoneal glucose tolerance test (IPGTT) and insulin tolerance test (IPITT) were performed. We determined the serum insulin and glucagon levels by ELISA kits and calculated insulin resistance index (HOME-IR). HE staining was used to observe the morphologies of pancreas and liver in mice. The damage of pancreatic beta cells was evaluated by TUNEL staining and immunofluorescence. We found the following: (1) compared with the DM group, the food intake and weight increase rate of artemether group significantly reduced ( < 0.05); (2) compared with pretreatment, artemether significantly reduced the fasting blood glucose levels, and the areas under the curves (AUCs) of IPGTT were decreased significantly, increasing the tolerance to glucose of db/db mice. ( < 0.05); (3) artemether improved hyperinsulinemia and decreased the AUCs of IPITT and HOME-IR, increasing the insulin sensitivity of db/db mice. (4) Artemether significantly ameliorated islet vacuolar degeneration and hepatic steatosis in db/db mice. (5) Artemether reduced the apoptosis of pancreatic beta cells and increased insulin secretion in db/db mice compared with DM group ( < 0.05). Our results indicated that artemether significantly improved glucose homeostasis and insulin resistance and had the potential activity to prevent obesity, reduced the severity of fatty liver, and protected pancreatic beta cells, promising to treat type 2 diabetes.
这项研究旨在探讨青蒿琥酯对 2 型糖尿病 db/db 小鼠的作用。实验分为三组:正常对照组(NC,db/+,1%甲基纤维素,灌胃)、糖尿病对照组(DM,db/db,1%甲基纤维素,灌胃)和青蒿琥酯治疗组(artemether,db/db,200mg/kg 青蒿琥酯,灌胃)。治疗持续两周。每三天测量一次小鼠的摄食量、体重和空腹血糖。实验开始和结束时,进行腹腔内葡萄糖耐量试验(IPGTT)和胰岛素耐量试验(IPITT)。通过 ELISA 试剂盒测定血清胰岛素和胰高血糖素水平,并计算胰岛素抵抗指数(HOME-IR)。用 HE 染色观察小鼠胰腺和肝脏的形态。通过 TUNEL 染色和免疫荧光评估胰岛β细胞的损伤。我们发现:(1)与 DM 组相比,青蒿琥酯组的摄食量和体重增长率明显降低(<0.05);(2)与预处理相比,青蒿琥酯明显降低了空腹血糖水平,IPGTT 的曲线下面积(AUC)明显降低,提高了 db/db 小鼠对葡萄糖的耐受性(<0.05);(3)青蒿琥酯改善了高胰岛素血症,降低了 IPITT 和 HOME-IR 的 AUC,提高了 db/db 小鼠的胰岛素敏感性。(4)青蒿琥酯显著改善了 db/db 小鼠胰岛空泡变性和肝脂肪变性。(5)与 DM 组相比,青蒿琥酯降低了 db/db 小鼠胰岛β细胞的凋亡,增加了胰岛素的分泌(<0.05)。我们的结果表明,青蒿琥酯显著改善了葡萄糖稳态和胰岛素抵抗,具有预防肥胖、减轻脂肪肝严重程度和保护胰岛β细胞的潜力,有望治疗 2 型糖尿病。